Therapeutic improvement of glucoregulation in newly diagnosed type 2 diabetes patients is associated with a reduction of IL-17 levels

Immunobiology

Volumn 218, Issue 8, 2013, Pages 1113-1118

  Sumarac Dumanovic, Mirjana ^a   Jeremic, Danka ^a   Pantovic, Aleksandar ^a   Janjetovic, Kristina ^a   Stamenkovic Pejkovic, Danica ^a   Cvijovic, Goran ^a   Stevanovic, Darko ^a   Micic, Dragan ^a   Trajkovic, Vladimir ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Diabetes type 2; Glycated hemoglobin; Metformin; Th1; Th17

Indexed keywords

GAMMA INTERFERON; HEMOGLOBIN A1C; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; METFORMIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-17; INTERLEUKIN-23; MALE; METFORMIN; MIDDLE AGED; TH1 CELLS; TH17 CELLS;

EID: 84878545299     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2013.03.002     Document Type: Article

References (46)

1. Aas A.M., Seljeflot I., Torjesen P.A., Diep L.M., Thorsby P.M., Birkeland K.I. Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes. Diabetologia 2006, 49:872-880.
2. Ahmed M., Gaffen S.L. IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev. 2010, 21:449-453.
3. American Diabetes Association Standards of medical care in diabetes - 2010. Diabetes Care 2010, 33(Suppl. 1):S11-S61.
4. Arif S., Moore F., Marks K., Bouckenooghe T., Dayan C.M., Planas R., Vives-Pi M., Powrie J., Tree T., Marchetti P., Huang G.C., Gurzov E.N., Pujol-Borrell R., Eizirik D.L., Peakman M. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated beta-cell death. Diabetes 2011, 60:2112-2119.
5. Belalcazar L.M., Reboussin D.M., Haffner S.M., Hoogeveen R.C., Kriska A.M., Schwenke D.C., Tracy R.P., Pi-Sunyer F.X., Ballantyne C.M. A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care 2010, 33:2297-2303.
6. Canto C., Auwerx J. Calorie restriction: is AMPK a key sensor and effector?. Physiology (Bethesda) 2011, 26:214-224.
7. Carter A.M., Bennett C.E., Bostock J.A., Grant P.J. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus. Diabet. Med. 2005, 22:1282-1284.
8. Cheng X., Yu X., Ding Y.J., Fu Q.Q., Xie J.J., Tang T.T., Yao R., Chen Y., Liao Y.H. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin. Immunol. 2008, 127:89-97.
9. Dardalhon V., Korn T., Kuchroo V.K., Anderson A.C. Role of Th1 and Th17 cells in organ-specific autoimmunity. J. Autoimmun. 2008, 31:252-256.
10. Donath M.Y., Boni-Schnetzler M., Ellingsgaard H., Ehses J.A. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009, 24:325-331.
11. Dula S.B., Jecmenica M., Wu R., Jahanshahi P., Verrilli G.M., Carter J.D., Brayman K.L., Nunemaker C.S. Evidence that low-grade systemic inflammation can induce islet dysfunction as measured by impaired calcium handling. Cell Calcium 2010, 48:133-142.
12. Esposito K., Ciotola M., Maiorino M.I., Giugliano D. Lifestyle approach for type 2 diabetes and metabolic syndrome. Curr. Atheroscler. Rep. 2008, 10:523-528.
13. Evia-Viscarra M.L., Rodea-Montero E.R., Apolinar-Jimenez E., Munoz-Noriega N., Garcia-Morales L.M., Leanos-Perez C., Figueroa-Barron M., Sanchez-Fierros D., Reyes-Garcia J.G. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial. J. Pediatr. Endocrinol. Metab. 2012, 25:41-49.
14. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol. 2005, 115:911-919. quiz 920.
15. Festa A., D'Agostino R., Tracy R.P., Haffner S.M. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131-1137.
16. Fidan E., Onder Ersoz H., Yilmaz M., Yilmaz H., Kocak M., Karahan C., Erem C. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol. 2011, 48:297-302.
17. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 2009, 9:556-567.
18. Gaffen S.L. Recent advances in the IL-17 cytokine family. Curr. Opin. Immunol. 2011, 23:613-619.
19. Greenfield J.R., Campbell L.V. Relationship between inflammation, insulin resistance and type 2 diabetes: 'cause or effect'?. Curr. Diabetes Rev. 2006, 2:195-211.
20. Hashmi S., Zeng Q.T. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron. Artery Dis. 2006, 17:699-706.
21. Jagannathan-Bogdan M., McDonnell M.E., Shin H., Rehman Q., Hasturk H., Apovian C.M., Nikolajczyk B.S. Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J. Immunol. 2011, 186:1162-1172.
22. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
23. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu. Rev. Immunol. 2009, 27:485-517.
24. Madhur M.S., Lob H.E., McCann L.A., Iwakura Y., Blinder Y., Guzik T.J., Harrison D.G. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010, 55:500-507.
25. Mathur N., Pedersen B.K. Exercise as a mean to control low-grade systemic inflammation. Mediators Inflamm. 2008, 2008:109502.
26. Miljkovic D., Trajkovic V. Inducible nitric oxide synthase activation by interleukin-17. Cytokine Growth Factor Rev. 2004, 15:21-32.
27. Miljkovic D., Cvetkovic I., Momcilovic M., Maksimovic-Ivanic D., Stosic-Grujicic S., Trajkovic V. Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells. Cell. Mol. Life Sci. 2005, 62:2658-2668.
28. Nath N., Khan M., Paintlia M.K., Singh I., Hoda M.N., Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol. 2009, 182:8005-8014.
29. Noh Y.H., Lee S.M., Kim E.J., Kim D.Y., Lee H., Lee J.H., Lee J.H., Park S.Y., Koo J.H., Wang J.H., Lim I.J., Choi S.B. Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion. Diabetes Metab. Res. Rev. 2008, 24:384-391.
30. Ohshima K., Mogi M., Jing F., Iwanami J., Tsukuda K., Min L.J., Higaki J., Horiuchi M. Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance. Hypertension 2012, 59:493-499.
31. Onishi R.M., Gaffen S.L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010, 129:311-321.
32. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813-823.
33. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286-1292.
34. Pradhan A.D., Everett B.M., Cook N.R., Rifai N., Ridker P.M. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 2009, 302:1186-1194.
35. Richter E.A., Ruderman N.B. AMPK and the biochemistry of exercise: implications for human health and disease. Biochem. J. 2009, 418:261-275.
36. Saenz A., Fernandez-Esteban I., Mataix A., Ausejo M., Roque M., Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2005, CD002966.
37. Salminen A., Hyttinen J.M., Kaarniranta K. AMP-activated protein kinase inhibits NF-kappaB signaling and inflammation: impact on healthspan and lifespan. J. Mol. Med. (Berl.) 2011, 89:667-676.
38. Santos V.R., Ribeiro F.V., Lima J.A., Napimoga M.H., Bastos M.F., Duarte P.M. Cytokine levels in sites of chronic periodontitis of poorly controlled and well-controlled type 2 diabetic subjects. J. Clin. Periodontol. 2010, 37:1049-1058.
39. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J. Clin. Invest. 2006, 116:1793-1801.
40. Sjoholm A., Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab. Res. Rev. 2006, 22:4-10.
41. Spranger J., Kroke A., Mohlig M., Hoffmann K., Bergmann M.M., Ristow M., Boeing H., Pfeiffer A.F. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817.
42. Sumarac-Dumanovic M., Stevanovic D., Ljubic A., Jorga J., Simic M., Stamenkovic-Pejkovic D., Starcevic V., Trajkovic V., Micic D. Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int. J. Obes. (Lond.) 2009, 33:151-156.
43. Takebayashi K., Aso Y., Inukai T. Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes. Metabolism 2004, 53:693-699.
44. Tan K.C., Chow W.S., Tam S., Bucala R., Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 2004, 27:223-228.
45. Winer S., Paltser G., Chan Y., Tsui H., Engleman E., Winer D., Dosch H.M. Obesity predisposes to Th17 bias. Eur. J. Immunol. 2009, 39:2629-2635.
46. Ye J., Keller J.N. Regulation of energy metabolism by inflammation: a feedback response in obesity and calorie restriction. Aging (Albany, NY) 2010, 2:361-368.